Literature DB >> 26379085

Practical designs for Phase I combination studies in oncology.

Nolan A Wages1, Anastasia Ivanova2, Olga Marchenko3.   

Abstract

Phase I trials evaluating the safety of multidrug combinations are becoming more common in oncology. Despite the emergence of novel methodology in the area, it is rare that innovative approaches are used in practice. In this article, we review three methods for Phase I combination studies that are easy to understand and straightforward to implement. We demonstrate the operating characteristics of the designs through illustration in a single trial, as well as through extensive simulation studies, with the aim of increasing the use of novel approaches in Phase I combination studies. Design specifications and software capabilities are also discussed.

Entities:  

Keywords:  Continual reassessment method; Phase I trials; dose finding; drug combination; partial ordering

Mesh:

Year:  2016        PMID: 26379085      PMCID: PMC4720553          DOI: 10.1080/10543406.2015.1092029

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  37 in total

1.  Designs for single- or multiple-agent phase I trials.

Authors:  Mark R Conaway; Stephanie Dunbar; Shyamal D Peddada
Journal:  Biometrics       Date:  2004-09       Impact factor: 2.571

2.  Two-dimensional dose finding in discrete dose space.

Authors:  Kai Wang; Anastasia Ivanova
Journal:  Biometrics       Date:  2005-03       Impact factor: 2.571

3.  A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials.

Authors:  Akihiro Hirakawa; Chikuma Hamada; Shigeyuki Matsui
Journal:  Stat Med       Date:  2013-05-06       Impact factor: 2.373

4.  Bayesian optimal interval design for dose finding in drug-combination trials.

Authors:  Ruitao Lin; Guosheng Yin
Journal:  Stat Methods Med Res       Date:  2015-07-15       Impact factor: 3.021

5.  A hierarchical Bayesian design for phase I trials of novel combinations of cancer therapeutic agents.

Authors:  Thomas M Braun; Shufang Wang
Journal:  Biometrics       Date:  2010-09       Impact factor: 2.571

6.  Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.

Authors:  Leena Gandhi; Rastislav Bahleda; Sara M Tolaney; Eunice L Kwak; James M Cleary; Shuchi S Pandya; Antoine Hollebecque; Richat Abbas; Revathi Ananthakrishnan; Anna Berkenblit; Mizue Krygowski; Yali Liang; Kathleen W Turnbull; Geoffrey I Shapiro; Jean-Charles Soria
Journal:  J Clin Oncol       Date:  2013-12-09       Impact factor: 44.544

7.  Competing designs for drug combination in phase I dose-finding clinical trials.

Authors:  M-K Riviere; F Dubois; S Zohar
Journal:  Stat Med       Date:  2014-01-27       Impact factor: 2.373

8.  A Bayesian case study in oncology Phase I combination dose-finding using logistic regression with covariates.

Authors:  Stuart Bailey; Beat Neuenschwander; Glen Laird; Michael Branson
Journal:  J Biopharm Stat       Date:  2009       Impact factor: 1.051

Review 9.  Adaptive designs for dual-agent phase I dose-escalation studies.

Authors:  Jennifer A Harrington; Graham M Wheeler; Michael J Sweeting; Adrian P Mander; Duncan I Jodrell
Journal:  Nat Rev Clin Oncol       Date:  2013-03-19       Impact factor: 66.675

10.  A product of independent beta probabilities dose escalation design for dual-agent phase I trials.

Authors:  Adrian P Mander; Michael J Sweeting
Journal:  Stat Med       Date:  2015-01-29       Impact factor: 2.373

View more
  2 in total

Review 1.  Anti-cancer drug combinations approved by US FDA from 2011 to 2021: main design features of clinical trials and role of pharmacokinetics.

Authors:  Salvador Fudio; Alvaro Sellers; Laura Pérez Ramos; Beatriz Gil-Alberdi; Ali Zeaiter; Mikel Urroz; Antonio Carcas; Rubin Lubomirov
Journal:  Cancer Chemother Pharmacol       Date:  2022-08-27       Impact factor: 3.288

2.  Revisiting isotonic phase I design in the era of model-assisted dose-finding.

Authors:  Nolan A Wages; Mark R Conaway
Journal:  Clin Trials       Date:  2018-08-13       Impact factor: 2.486

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.